RSVpreF Approval for Older Adults Follows Positive Results of RENOIR Trial

Oct 3, 2023

The FDA’s approval of a bivalent RSV prefusion F (RSVpreF) vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older was based on data from the phase 3 RENOIR trial. The...

Most Infants With RSV-Related Critical Illness Born at Term

Oct 2, 2023

Most infants requiring intensive care for respiratory syncytial virus are born at term, and do not...

Only Half of Older Adults Have Heard of New RSV Vaccine

Oct 1, 2023

About half of older adults (52 percent) have heard of the new vaccine against respiratory...

Follow Us

Ad Code: RSV - RSV - Display Banners HCP Wallboard Extension - 53430

RSVpreF Approval for Older Adults Follows Positive Results of RENOIR Trial

Most Infants With RSV-Related Critical Illness Born at Term

Only Half of Older Adults Have Heard of New RSV Vaccine